PMID- 22466790
OWN - NLM
STAT- MEDLINE
DCOM- 20130325
LR  - 20131121
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 93
IP  - 12
DP  - 2012 Jun 27
TI  - Posttransplant major histocompatibility complex class I chain-related gene A 
      antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney 
      transplant recipients.
PG  - 1258-64
LID - 10.1097/TP.0b013e31824fd8f1 [doi]
AB  - BACKGROUND: The impact of major histocompatibility class I chain-related A (MICA) 
      antibodies on renal graft outcomes is unclear. The goal of this work was to 
      assess the impact of posttransplant MICA antibodies, assayed at 1 year, with two 
      commercially available kits, on long-term renal graft outcomes. METHODS: We 
      retrospectively tested sera from 779 kidney transplant recipients with two 
      single-antigen flow bead assays 1 year after transplantation. Samples were 
      considered positive for MICA if they were positive in both tests or positive for 
      MICA specificities that were present in one kit only. The main outcome was 4-year 
      death-censored graft survival. RESULTS: The prevalence of MICA antibodies was 
      5.4% at 1 year. MICA+ patients were more frequently human leukocyte antigen (HLA) 
      sensitized and regrafted. Four-year death-censored graft survival was not 
      different between MICA+ and MICA- patients (97% vs. 94%, P=0.28). By Cox 
      multivariate analysis, independent risk factors for graft loss were as follows: 
      number of HLA DR mismatches, acute rejection within the first year 
      posttransplantation, 1-year serum creatinine, and the presence of HLA antibodies 
      at 1 year, but not the presence of MICA antibodies. CONCLUSIONS: These data do 
      not support an independent pathogenic role for MICA in long-term renal graft 
      injury and question the interest of posttransplant monitoring of MICA antibodies 
      with single-antigen flow bead assays currently available.
FAU - Lemy, Anne
AU  - Lemy A
AD  - Renal Transplantation Clinic, Erasme Hospital, Brussels, Belgium. 
      Anne.Lemy@erasme.ulb.ac.be
FAU - Andrien, Marc
AU  - Andrien M
FAU - Lionet, Arnaud
AU  - Lionet A
FAU - Labalette, Myriam
AU  - Labalette M
FAU - Noel, Christian
AU  - Noel C
FAU - Hiesse, Christian
AU  - Hiesse C
FAU - Delahousse, Michel
AU  - Delahousse M
FAU - Suberbielle-Boissel, Caroline
AU  - Suberbielle-Boissel C
FAU - De Meyer, Martine
AU  - De Meyer M
FAU - Latinne, Dominique
AU  - Latinne D
FAU - Mourad, Michel
AU  - Mourad M
FAU - Delsaut, Severine
AU  - Delsaut S
FAU - Racape, Judith
AU  - Racape J
FAU - Wissing, Karl M
AU  - Wissing KM
FAU - Toungouz, Michel
AU  - Toungouz M
FAU - Abramowicz, Daniel
AU  - Abramowicz D
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Isoantibodies)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Creatinine/blood
MH  - Female
MH  - Graft Rejection/*immunology/*mortality
MH  - Graft Survival/*immunology
MH  - HLA-A Antigens/*immunology
MH  - HLA-DR Antigens/immunology
MH  - Humans
MH  - Isoantibodies/immunology
MH  - Kidney Transplantation/*immunology/*mortality
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Seroepidemiologic Studies
EDAT- 2012/04/03 06:00
MHDA- 2013/03/26 06:00
CRDT- 2012/04/03 06:00
PHST- 2012/04/03 06:00 [entrez]
PHST- 2012/04/03 06:00 [pubmed]
PHST- 2013/03/26 06:00 [medline]
AID - 10.1097/TP.0b013e31824fd8f1 [doi]
PST - ppublish
SO  - Transplantation. 2012 Jun 27;93(12):1258-64. doi: 10.1097/TP.0b013e31824fd8f1.